Professional Documents
Culture Documents
DRUGS
BY
DR/AZZA BARAKA
Learning objectives
Classify the antihyperlipidemic drugs.
Explain the mechanism of action of drugs used
in treatment of hypercholesterolemia &
hypertriglyceridemia.
Deduce the different antihyperlipidemic drugs in
treatment of combined hyperlipidemia.
Tabulate the difference between the different
antihyperlipidemic drugs as regards;
mechanism of action, side effects & therapeutic
uses.
Lipids originate from two sources: endogenous lipids, synthesized in the liver,
and exogenous lipids, ingested and processed in the intestine.
Cholesterol can be
LDLreceptor converted to bile salts
Peripheral mediated for excretion or
tissues LDL endocytosis LDL repackaged in VLDL
for redistribution
Pharmacotherapeutic options in
hyperlipidemia
I-Agents targeting endogenous cholesterol:
a-Statins.
b-Fibrates.
C-Nicotinic acid.
II-Agents Targeting Exogenous Cholesterol
a-Cholesterol Uptake Inhibitors, e.g. ezetemibe.
b- Bile acid binding resins, e.g. colestipol &
cholestyramine
H M G – COA REDUCTASE
INHIBITORS(STATINS)
Lovastatin , fluvastatin , pravastatin ,
simvastatin ,atorvastatin and rosuvastatin.
Pharmacokinetics:
They are subjected to extensive first-pass
metabolism by the liver. Greater than 95% of
most of these drugs are bound to plasma
proteins.
All statins are taken orally at bedtime because of
diurnal rhythm of cholesterol synthesis,
except atorvastatin taken at any time
because of its long half-life (14 hours).
Mechanism of action
These are potent reversible competitive
inhibitors of 3-hydroxy 3-methyl glutaryl
coenzyme A reductase, the rate-controlling
enzyme in cholesterol biosynthesis.
They are extremely effective in lowering plasma
concentration of LDL-C.
They act by inhibiting cholesterol synthesis in
the liver, so they deplete the intracellular supply
of cholesterol, which in turn triggers a
compensatory up-regulation of hepatic LDL
receptors, thus, causing increased clearance of
plasma LDL .
Pharmacological actions
Effect on LDL-C: Statins decrease LDL-C by two
mechanisms:
Up-regulation of LDL-R with increase of clearance of LDL-C
and decrease LDL-C.
Decrease of very low density lipoprotein (VLDL) production
because cholesterol is a required component of VLDL which
is a precursor of LDL-C
Effect on VLDL: Decreased VLDL production mediated
by decreased C, a required component of VLDL.
Effect on HDL-C: Statins induce modest increase in
HDL-C, this might be due to the ability of statins to
reduce plasma CETP activity (mediates the transfer of
cholesteryl esters from HDL to apoB-containing
lipoproteins in exchange for triglycerides).
Adverse effects
1. Hepatotoxicity (increased serum transaminase).
2. Myopathy (increased creatine kinase) especially
when combined with:
other lipid lowering drugs: i)Fibrates. ii) Niacin.
other drugs that are metabolized by 3A4 isoform of
cytochrome P450 e.g.: erythromycin, cyclosporine,
verapamil, ketoconazole.
1. G.I.T upset.
2. Headache.
N.B: liver transaminases and CK must be regularly
measured during therapy with statins
Contraindications
1. Pregnancy & lactation (Cholesterol is important for normal
development, and it is possible that statins could cause serious
problems). The effects of high cholesterol do not cause
problems for many years or even decades. Therefore, if a
woman does not take her statin or other cholesterol
medications during breastfeeding, it will likely have only a
minimal impact on her long-term risks. Therefore, it is best to
wait until you have weaned your child before starting or
resuming a statin medication
2. Active liver diseases.
N.B. The American Academy of Pediatrics is recommending that
kids as young as 8 years old be given cholesterol drugs in hope
of preventing future heart disease.
Drug interactions
Potentiate the action of oral anticoagulant and
antidiabetic drugs (displacement from plasma
protein binding sites).
N.B. : Pravastatin and fluvastatin are the statins
of choice to be given to a patient taking other
drugs metabolized by cytochrome 3A4 system.
(FIBRIC ACID DERIVATIVE (Fibrates
Preparations: Gemfibrozil , fenofibrate , clofibrate .
Mechanism of action:
Ligand for the nuclear transcription regulator, peroxisome proliferator-
activated receptor-α (PPAR- α) in the liver, heart, kidney, &
skeletal muscle. N.B The PPAR-a are a class of intracellular
receptors that modulate fat metabolism. It is through PPAR-a that
fibrates lead to:
Increased LPL activity, which increases clearance of VLDL &
chylomicron in plasma.
Increased FFA uptake by the liver.
Decreased VLDL due to increased fatty acid metabolism( beta
oxidation), by inducing Acyl-coenzymeA synthetases , which is a crucial
enzyme that facilitate the uptake and permit the metabolism of fatty acids.
Increased LDL-C uptake by the liver.
Raises HDL cholesterol levels (by increasing Apo A-I and II
expression in hepatocytes).
Increase excretion of hepatic cholesterol in bile , thus endogenous
hepatic cholesterol synthesis may be decreased.
PPARs
PPARs functions as a ligand-activated transcription factor.
Upon binding to hypolipidemic drugs, PPARs are activated.
They then bind to peroxisome proliferator response elements,
which are localized in numerous gene promoters. In particular,
PPARs regulates the expression of genes encoding for proteins
involved in lipoprotein structure and function.
Several such genes have been identified, including those of
apoC-III, apoA-I, apoA-II, apoA-IV, acyl coenzyme A oxidase,
and possibly that of lipoprotein lipase.
The transcriptional downregulation of apoC-III and the
upregulation of lipoprotein lipase by fibrates enhance both the
intravascular lipolysis of TG-rich lipoproteins as well as their
tissue catabolism via apoE-mediated binding to specific cellular
receptors.
Adverse effects
G.I.T upset,rash, urticaria
Myopathy
Since fibrates increase the cholesterol content
of bile, they increase the risk for gallstones.
Drug interactions
1. Increased risk of myopathy when combined with
statins.
2. Displace drugs from plasma proteins( e.g. oral
anticoagulants and oral hypoglycemic drugs).
Contraindications:
1- Patients with impaired renal functions.
2- Pregnant or nursing women.
3-Preexisting gall bladder disease.
NICOTINIC ACID(NIACIN)
Mechanism of action:
1. In adipose tissue: it binds to adipose nicotinic acid receptors, this
will lead to decrease in free fatty acids mobilization from
adipocytes to the liver resulting in ↓ TG and thus VLDL synthesis.
2. In liver: niacin inhibits hepatocyte diacylglycerol acyltransferase-2,
a key enzyme for TG synthesis. Thus, it decreases VLDL
production (decreased TG synthesis and estrification).
3. In plasma: it increases LPL activity that increases clearance of
VLDL & chylomicron.
1. Gout.
2. Peptic ulcer.
3. Hepatotoxicity.
4. Diabetes mellitus.
Ezetimibe
Mechanism of action:
- Impairs dietary and biliary cholesterol absorption at the
brush border of the intestines without affecting fat-soluble
vitamins.
- Reducing the pool of cholesterol absorbed from the diet
results in a reduced pool of cholesterol available to the liver.
-The liver in turn will upregulate the LDL receptor,
trapping more LDL particles from the blood and result in a
fall in measured LDL cholesterol .
Adapted from van Heek M et al Br J Pharmacol 2000;129:1748-1754.
Pharmacokinetics